ANTI HYPERTENSIVE DRUGS FOR PULMONARY ARTERIAL HYPERTENSION (PAH) IN INTERNATIONAL PHARMACOVIGILANCE: DATA MINING STUDY
V. Lavanya*, Y. Anil Kumar, Konda Ravi Kumar and K. S. D. V. Surya Kiran
Precapillary pulmonary hypertension with a mean pulmonary artery pressure of >25 mm Hg and a normal pulmonary artery wedge pressure of <15mmhg is pulmonary arterial hypertension signs and symptoms of PAH are similar to those of heart & lung conditions. The prevalence of PAH is thought to be range of 15-50 subjects per million population in Europe. Biological factors, chemical factors genetical factors are the confounding risk factors for PAH drug use PAH can be associated with exposure to certain drugs or toxins, particularly to appetite suppressant intake drugs. PAH is a disease of precapillary pulmonary arterial bed, including the medium sized pulmonary arteries &pulmonary arteriols characterized by vascular obliteration widespread endothelial apoptosis result in proliferation of apoptosis resistant endothelial precursor cell & that proliferate & eventually form plexiform lessions PAH has a genetic component. The bone morphogenetic proteins (BMP) are part of the transforming growth factor superfamily (TGF-BETA). The disfunctional pulmonary hypertensive endothelial cell phenotype is characterized by uncontrolled proliferation increased production of vasoconstrictor mediators such as endothelin expression of 5-lipoxygenase & decreased synthesis of prostacyclin CCBS, ERAS,PD5 inhibitors, guanylate cyclase stimulators, prostacyclin IP receptors agonists are used for treatment of PAH.
[Full Text Article]